|
受注:045-509-1970 |
技術サポート:tech@selleck.co.jp 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
|
Synonyms | NSC 20256,β-Uridine, Uridin | Storage (From the date of receipt) |
3 years -20°C powder 1 years -80°C in solvent |
|||||||||||
| 化学式 | C9H12N2O6 |
||||||||||||||
| 分子量 | 244.2 | CAS No. | 58-96-8 | ||||||||||||
| Solubility (25°C)* | 体外 | DMSO | 49 mg/mL (200.65 mM) | ||||||||||||
| Water | 49 mg/mL (200.65 mM) | ||||||||||||||
| Ethanol | Insoluble | ||||||||||||||
| 体内 (毎回新しく調製した物を用意してください) |
|
||||||||||||||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. |
|||||||||||||||
| 製品説明 | Uridine (NSC 20256,β-Uridine, Uridin) is a nucleoside, contains a uracil attached to a ribose ring via a β-N1-glycosidic bond. |
|---|
| De novo pyrimidine synthesis is a collateral metabolic vulnerability in NF2-deficient mesothelioma [ EMBO Mol Med, 2025, 10.1038/s44321-025-00278-4] | PubMed: 40707702 |
| Targeting the MARCH5-MFN2 axis to enhance mitochondrial fusion and sensitize multiple myeloma cells to venetoclax [ J Transl Med, 2025, 23(1):917] | PubMed: 40814067 |
| Synergistic interference with SARS-CoV-2 replication by molnupiravir-derived N4-hydroxycytidine and inhibitors of CTP synthetase in cell culture [ Virology, 2025, 610:110598] | PubMed: 40561865 |
| Combined inactivation of CTPS1 and ATR is synthetically lethal to MYC-overexpressing cancer cells [ Cancer Res, 2022, canres.1707.2021] | PubMed: 35022212 |
| Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication [ iScience, 2022, 25(5):104293] | PubMed: 35492218 |
| Exploring Marine-Derived Ascochlorins as Novel Human Dihydroorotate Dehydrogenase Inhibitors for Treatment of Triple-Negative Breast Cancer [ J Med Chem, 2021, 64(18):13918-13932] | PubMed: 34516133 |
| N4-hydroxycytidine and inhibitors of dihydroorotate dehydrogenase synergistically suppress SARS-CoV-2 replication [ bioRxiv, 2021, 10.1101/2021.06.28.450163] | PubMed: N/A |
| N4-hydroxycytidine and inhibitors of dihydroorotate dehydrogenase synergistically suppress SARS-CoV-2 replication [ bioRxiv, 2021, 10.1101/2021.06.28.450163] | PubMed: None |
長期の保管のために-20°Cの下で製品を保ってください。
人間や獣医の診断であるか治療的な使用のためにでない。
各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。